Recent Updates
Recently added Catalysts
VIR Positive Sentiment

Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders

Key Takeaway: Vir Biotechnology, Inc. will host its 2023 Annual General Meeting of Stockholders on May 19, 2023, at 11:30 a.m. PT. The meeting will take place in a virtual format, allowing stockholders to attend through a live audio webcast. Stockholders of record can vote during the meeting by accessing the provided meeting center link. The company encourages stockholders to submit their proxies in advance of the meeting.
Price reaction · baseline $24.87 (2023-05-16 close) · hit after-hours · clean, no other VIR news in the window
day 0 close · peak
+0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • The annual meeting allows stockholders to participate virtually, enhancing accessibility.
  • Vir Biotechnology is actively engaging with its stockholders by urging them to vote in advance.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
14%
average across 4 past catalysts
Lead asset
Tobevibart
Phase 3 · Viral Hepatitis

Full Press Release Details

SAN FRANCISCO, May 17, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19, 2023, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast.
Vir Biotechnology’s stockholders of record as of March 30, 2023 (the “Record Date”) can attend and vote at the Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/VIR2023 and entering the control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received. Instructions on how to connect to the Annual Meeting and participate via the Internet are also posted at www.virtualshareholdermeeting.com/VIR2023. Online access to the Annual Meeting will begin at 11:15 a.m. PT. Stockholders should allow ample time for the check-in procedures.
Whether or not stockholders plan to virtually attend the Annual Meeting, Vir Biotechnology urges them to vote and submit their proxy in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.

Frequently Asked Questions

When is the Vir Biotechnology Annual Meeting scheduled?

The Annual Meeting is set for May 19, 2023, at 11:30 a.m. PT.

How can stockholders attend the Annual Meeting?

Stockholders can attend the meeting virtually via www.virtualshareholdermeeting.com/VIR2023.

What should stockholders do before the Annual Meeting?

Stockholders are encouraged to vote and submit their proxy in advance.

What technology platforms does Vir Biotechnology utilize?

Vir uses four technology platforms to enhance the immune system's response.

What diseases does Vir Biotechnology focus on treating?

Vir focuses on treating COVID-19, hepatitis B and D, influenza A, and HIV.

Last updated: May 17, 2023